innovation management: experience from the danish biotech ...€¦ · alexander innovation zone...

Alexander Innovation ZoneAlexander Innovation ZoneThessaloniki, GreeceThessaloniki, Greece

Biotechnology clustersBiotechnology clustersInnovation management: Innovation management:

experience from the Danish experience from the Danish biotech cluster of Aarhusbiotech cluster of AarhusPlans for a Biotech Cluster within the Plans for a Biotech Cluster within the

Thessaloniki Innovation ZoneThessaloniki Innovation Zone

((prepared for Aristotle University of prepared for Aristotle University of Thessaloniki,Thessaloniki,

School of Architecture, Jan 18, 2008)School of Architecture, Jan 18, 2008)IordanisIordanis ArzimanoglouArzimanoglou, Ph.D., Ph.D.


BioKoreaBioKorea 2007 Conference2007 ConferenceBiotechnologyBiotechnology CompaniesCompaniesPharmaceuticalPharmaceutical CompaniesCompaniesBioBioResearchResearch InstitutionsInstitutionsVentureVenture CapitalCapital InvestorsInvestors with focus innovative with focus innovative bioproductsbioproductsBioterndBioternd: : BioBio--clustersclusters/Bionetworks/Innovation Zones/Bionetworks/Innovation Zones--PromotePromote policiespolicies toto supportsupport thethe biobio industryindustry, , --IdentifyIdentify technologytechnology transfertransfer opportunitiesopportunities, , --NetworkNetwork withwith biobio companiescompanies andand researchresearch centerscenters acrossacross thetheworldworld--AttractAttract InvestmentInvestment intointo bibigg companiescompanies


The 10The 10thth Annual Annual BioCEOBioCEO and and Investor ConferenceInvestor Conference

New York, Feb 11, 2008New York, Feb 11, 2008BIO CEOBIO CEO MISSION:MISSION: BIO BIO bringsbrings togethertogether biotechnologybiotechnology CEOsCEOs, , membersmembers ofof thethe

investmentinvestment communitycommunity andand otherother keykey industryindustry supporterssupporters inin a a neutralneutral andand collaborativecollaborativeforumforum toto examineexamine investmentinvestment opportunitiesopportunities andand issuesissues affectingaffecting thethe industryindustry..

TARGET AUDIENCE:TARGET AUDIENCE: PublicPublic andand privateprivate equityequity investorsinvestors, , researchresearch analystsanalysts, , investmentinvestmentbankersbankers andand seniorsenior--levellevel industryindustry executivesexecutives focusedfocused onon investmentinvestment trendstrends andand businessbusinessdevelopmentdevelopment opportunitiesopportunities inin thethe biotechnologybiotechnology industryindustry..

WhyWhy CompaniesCompanies AttendAttend::PresentPresent companycompany storystory toto anan audienceaudience ofof targettarget investorsinvestorsMeetMeet oneone--onon--oneone withwith investorsinvestors, , analystsanalysts, , investinvest..bankersbankers andand potentialpotential corporatecorporatepartnerspartnersHearHear panelpanel discussionsdiscussions andand keynoteskeynotes byby veteranveteran investmentinvestment andand companycompany executivesexecutivesNetworkNetwork withwith peerspeers, , investorsinvestors andand potentialpotential partnerspartners attendingattending thethe conferenceconferenceGetGet thethe pulsepulse onon thethe currentcurrent andand proposedproposed investmentinvestment trendstrends inin biotechnologybiotechnology

WhyWhy InvestorsInvestors AttendAttend::HearHear fromfrom andand meetmeet oneone--onon--oneone withwith managementmanagement fromfrom thethe toptop biotechbiotech companiescompaniesEvaluateEvaluate freshfresh investmentinvestment opportunitiesopportunities includingincluding compatiblecompatible, , complementarycomplementary andandcompetitivecompetitive companiescompaniesAttendAttend candidcandid panelpanel discussionsdiscussions withwith leadingleading clinicalclinical expertsexperts andand companycompany expertsexperts ononthethe latestlatest therapiestherapies andand technologiestechnologies inin developmentdevelopmentGetGet a ‘a ‘bigbig picturepicture’ ’ overviewoverview ofof thethe industryindustry andand thethe issuesissues affectingaffecting investmentsinvestments


BiotrendBiotrend

Bioclusters/BioregionsBioclusters/BioregionsBionetworksBionetworks

Biopartnering organizations Biopartnering organizations Biomedical Science and Biomedical Science and

Technology Strategy UnitsTechnology Strategy Units


Biopolis, Singapore: Biopolis, Singapore: biocluster with pharma R/D centersbiocluster with pharma R/D centers

Pharmaceutical giant GlaxoSmithKline invested $37 M Pharmaceutical giant GlaxoSmithKline invested $37 M on a on a

research facility focusing on new therapies for research facility focusing on new therapies for Alzheimer's, Alzheimer's,

Parkinson's and other neuroParkinson's and other neuro--degenerative diseases. The degenerative diseases. The facility will be housed in the statefacility will be housed in the state--ofof--thethe--art laboratories art laboratories

of of the the Biopolis, Singapore's highBiopolis, Singapore's high--end biomedical research end biomedical research center,center, GSK said in a statement. GSK said in a statement. Singapore’s ConcernSingapore’s Concern: What might happen if the big : What might happen if the big pharmaceutical companies decide to move their R/D pharmaceutical companies decide to move their R/D

deptsdepts


Biocluster formation around Biocluster formation around Pfizer’s Research Technology Pfizer’s Research Technology

Center (RTC)Center (RTC)RTC involves innovative science to identify RTC involves innovative science to identify and validate drug discovery targets for Pfizerand validate drug discovery targets for PfizerRTC is surrounded by 300 biotech RTC is surrounded by 300 biotech companies and worldcompanies and world--leading research leading research hospitals and academic institutions hospitals and academic institutions (biocluster formation)(biocluster formation)The result of the biocluster is a growing The result of the biocluster is a growing number of partnerships and eventually a number of partnerships and eventually a dynamic portofolio for Pfizer dynamic portofolio for Pfizer


European bioclusters, bionetworksEuropean bioclusters, bionetworks

Medicon Valley AllianceMedicon Valley AllianceNetherlands Genomics Initiative (NGI), Netherlands Netherlands Genomics Initiative (NGI), Netherlands Flanders interFlanders inter--university Institute of Biotechnology university Institute of Biotechnology (VIB) Belgium(VIB) BelgiumBioLondon: London Biotechnology NetworkBioLondon: London Biotechnology Network

The aboveThe above--organizations aim to optimally integrate the organizations aim to optimally integrate the opportunities opportunities

offered by the genomics and biotechnology research in their offered by the genomics and biotechnology research in their respective respective

countries in order to create a continuous stream of countries in order to create a continuous stream of new bionew bio--business business

activityactivity


Medicon Valley Medicon Valley Academy/Alliance Academy/Alliance

biocluster biocluster (2 countries involved)(2 countries involved)MVA is a world class life science cluster MVA is a world class life science cluster organization organization for the Danishorganization organization for the Danish--Swedish life science cluster Swedish life science cluster MVA is a nonMVA is a non--profit, fee based member profit, fee based member organization taking cross border initiatives organization taking cross border initiatives creating synergies and value for over 250 creating synergies and value for over 250 members which include companies, hospitals members which include companies, hospitals and universities and universities


Medicon Valley Alliance Medicon Valley Alliance biocluster successbiocluster success

According to 3i, one of the biggest European According to 3i, one of the biggest European VCs with capitalization around 8 bn Euro VCs with capitalization around 8 bn Euro Medicon Valley Alliance has been very Medicon Valley Alliance has been very successful in marketing its biocluster. As a successful in marketing its biocluster. As a result of the cluster success, British investors result of the cluster success, British investors keep an eye on MVA companies keep an eye on MVA companies


Finnish model for biodevelopment Finnish model for biodevelopment across all the biochain: BioTurku across all the biochain: BioTurku

clustercluster


London Genetics tech London Genetics tech transfer bionetworktransfer bionetwork

Seven London institutes created “London Genetics” Seven London institutes created “London Genetics” bionetwork with focus on tech transfer to generate bionetwork with focus on tech transfer to generate and manage partnerships between leading and manage partnerships between leading researchers and the biotech and pharma industryresearchers and the biotech and pharma industryConsortium is composed of: King’s College Consortium is composed of: King’s College London, Univ. College London, Imperial College London, Univ. College London, Imperial College London, Quenn Mary, St George;s Univ. of London, Quenn Mary, St George;s Univ. of London, The London Scholl of Tropical Medicine London, The London Scholl of Tropical Medicine and Hygiene, and The Institute of Cancer Researchand Hygiene, and The Institute of Cancer Research


US biopartnering organizationsUS biopartnering organizations

Science Center in the Greater Philadelphia regionScience Center in the Greater Philadelphia region: it : it connencts scientists growing companies and connencts scientists growing companies and international companies, and VCs and focuses on international companies, and VCs and focuses on forming and funding new life sciences and technology forming and funding new life sciences and technology companiescompaniesNew Jersey New Jersey -- Commission on Science and TechnologyCommission on Science and TechnologyUS Georgia office of Science & technologyUS Georgia office of Science & technology: a division : a division specializing to recruit and support technology and life specializing to recruit and support technology and life sciences companies sciences companies The stateThe state--sponsored sponsored Biomedical Research & Biomedical Research & Technology Transfer Office and Fund, OhioTechnology Transfer Office and Fund, Ohio


Scandinavian networks in medical Scandinavian networks in medical technology technology (3 countries involved(3 countries involved))Finland, Norway and Sweden joined forces to Finland, Norway and Sweden joined forces to inform the US life sciences industry about the strong inform the US life sciences industry about the strong competencies in the Nordic countriescompetencies in the Nordic countriesThe objective was to partner small Nordic medtech The objective was to partner small Nordic medtech companies (specialized networked cluster) with US companies (specialized networked cluster) with US corporations and VCs thereby attracting more corporations and VCs thereby attracting more foreign investments in houseforeign investments in houseThe medtech industry in Denmark The medtech industry in Denmark accounted for accounted for 31% of the turnover in the Danish healthcare system31% of the turnover in the Danish healthcare systemin 2006in 2006


Commercialization of bioresearch: Commercialization of bioresearch: Strong EU political impactStrong EU political impact

A European strategy for more growth & jobs: A European strategy for more growth & jobs: What policies are requiredWhat policies are required to exploit R/D to exploit R/D breakthrough opportunitiesbreakthrough opportunitiesA biotech strategy at a regional European level is A biotech strategy at a regional European level is promoted promoted

the Gent/Flanders region, Belgium or the Gent/Flanders region, Belgium or the Aarhus regionthe Aarhus region, Denmark or, Denmark orthe Thessaloniki regionthe Thessaloniki region, Greece, etc., Greece, etc.

3rd European Business Summit, Brussels, Mar. 20043rd European Business Summit, Brussels, Mar. 2004


Danish experience: Danish experience: Aarhus biotechnology clusterAarhus biotechnology cluster


Aarhus

Copenhagen

Aarhus Biotechnology ClusterAarhus Biotechnology ClusterExperience from DenmarkExperience from Denmark


Aarhus remarkable Aarhus remarkable achievementsachievements

Nobel PrizeNobel Prize:: Prof. Jens Chr. Skou was awarded the Prof. Jens Chr. Skou was awarded the Nobel Prize in Chemistry in 1997 for his pioneering Nobel Prize in Chemistry in 1997 for his pioneering work in Physiology: the first discovery of an ion work in Physiology: the first discovery of an ion transporting enzyme.transporting enzyme.

Descartes PrizeDescartes Prize:: Prof. Lars Fugger was awarded the Prof. Lars Fugger was awarded the prestigious prestigious “little Nobel Prize”“little Nobel Prize” in 2002 for his work in 2002 for his work tackling Multiple Sclerosistackling Multiple Sclerosis

Research standard in clinical research:Research standard in clinical research: the Institute of the Institute of Clinical Medicine (AU) produces 1.5 Clinical Medicine (AU) produces 1.5 –– 2‰ of the 2‰ of the world's clinical research publications in peerworld's clinical research publications in peer--reviewed reviewed journalsjournals


Aarhus biotech clusterAarhus biotech clusterInnovation/first ranksInnovation/first ranks

First company in Europe to sign an agreement First company in Europe to sign an agreement with with Affymetrix Affymetrix to use its chipto use its chip for molecular for molecular profiling and develop molecular classifiers profiling and develop molecular classifiers First company in Denmark to First company in Denmark to produce GMO produce GMO plants as a vehicle to develop a therapeutic toolplants as a vehicle to develop a therapeutic toolagainst vitamin B12 deficiency, which can lead to against vitamin B12 deficiency, which can lead to AlzheimerAlzheimerFirst Biomedical Engineering educationFirst Biomedical Engineering education with with focus on entrepreneurship, 1999focus on entrepreneurship, 1999Danish pioneers inDanish pioneers in introduction & introduction & implementation of electronic patient journals implementation of electronic patient journals (EPJ)(EPJ)


Aarhus competitive research Aarhus competitive research fields due to innovationfields due to innovation

NanotechNanotech--center (center (www.inano.dkwww.inano.dk) ) The PET center (The PET center (www.pet.au.dkwww.pet.au.dk) ) XX--ray crystallography ray crystallography Water and salt centre, (Water and salt centre, (www.waterandsalt.au.dkwww.waterandsalt.au.dk): ): Nobel laureate: Nobel laureate: SchouSchouRNA analysis/delivery Centre (RNA analysis/delivery Centre (www.sirna.dkwww.sirna.dk))Biomedical EngineeringBiomedical Engineering


Aarhus, DenmarkAarhus, DenmarkLife Sciences and Biotechnology ClusterLife Sciences and Biotechnology Cluster

Products and ServicesProducts and Services

Health Care ITHealth Care IT

PervasivePervasiveHealth CareHealth Care

DiagnosticDiagnosticKitsKits

DrugDiscovery: technology

platform

Devices forDevices forrehabilitationrehabilitation DisposablesDisposables DiagnosticDiagnostic

devicesdevices


Aarhus ongoing collaborationAarhus ongoing collaborationwith big with big bioindustrybioindustry

General Electric, Philips, General Electric, Philips, FerringFerring, Bavarian , Bavarian

Nordic, Novo Nordisk, Nordic, Novo Nordisk, DaniscoDanisco, , LundbeckLundbeck, ,

Cambridge Antibody Technology, Cambridge Antibody Technology, ArlaArla Foods Foods


BMF/Biomedical Science Park, BMF/Biomedical Science Park, Aarhus, DenmarkAarhus, Denmark

BioMedicoBioMedico Forum (BMF) is a biotechnology research and Forum (BMF) is a biotechnology research and business strategy organization with overall aim to gain business strategy organization with overall aim to gain competitive advantage for the Aarhus region, Denmark. competitive advantage for the Aarhus region, Denmark.

More More specifically, tspecifically, the primary goals are to: he primary goals are to:

design strategy,design strategy,catalyzecatalyze, , support, and support, and coordinate coordinate

biotechnology development in the respective region biotechnology development in the respective region


BMF/Biomedical Science ParkBMF/Biomedical Science Park:: Members of the bionetworkMembers of the bionetwork

University Departments/Divisions University Departments/Divisions Hospital DivisionsHospital Divisions>50 Biotech and Med Tech start>50 Biotech and Med Tech start--up companies up companies >20 Biotech>20 Biotech--support firms with different business support firms with different business objectives e.g. IPR, bank high tech investment depts, objectives e.g. IPR, bank high tech investment depts, consulting, regulatory affairsconsulting, regulatory affairsRegional authorities Regional authorities


BMF strategy: BMF strategy: Aarhus biocluster as a virtual organizationAarhus biocluster as a virtual organization

Strategy Development for the Aarhus Strategy Development for the Aarhus bioclusterbioclusterin Denmark. in Denmark. According to this strategy, we According to this strategy, we envision the entire region as one virtual bioenvision the entire region as one virtual bio--organization. organization.

(New Economy strategy model: Specialized (New Economy strategy model: Specialized networked networked region vs selfregion vs self--contained regional cluster)contained regional cluster)


BMF strategy: BMF strategy: Aarhus biocluster as a virtual organizationAarhus biocluster as a virtual organization

BMF role includes:BMF role includes:Design strategy and business development plan Design strategy and business development plan for the entire bioregion/bioclusterfor the entire bioregion/bioclusterCoordinateCoordinate activities within the activities within the bioclusterbioclusterAcquire profound knowledge of the worldwide Acquire profound knowledge of the worldwide biotrends (e.g. biodefense in Denmark, is one of biotrends (e.g. biodefense in Denmark, is one of the fastestthe fastest--growing new sectors to develop growing new sectors to develop sensors, vaccines, etc)sensors, vaccines, etc)


BMF strategyBMF strategy: : Aarhus biocluster as a virtual organization Aarhus biocluster as a virtual organization

BMF role to:BMF role to:Gather a critical mass under Aarhus region Gather a critical mass under Aarhus region umbrellaumbrellaFocus on IP protection and commercialization of Focus on IP protection and commercialization of breakthrough discoveries breakthrough discoveries Tackle the seemingly problem: company Tackle the seemingly problem: company proprietary information vs sharing critical proprietary information vs sharing critical knowhow knowhow Develop the feeling of ownership from each Develop the feeling of ownership from each company and everyone involvedcompany and everyone involved


BMF strategyBMF strategy: : Innovation in foreign investment Innovation in foreign investment

policypolicyBMF & Invest in DenmarkBMF & Invest in Denmark

BMF provides “Invest in Denmark” (the Danish BMF provides “Invest in Denmark” (the Danish national inward organization) with critical national inward organization) with critical information about the Aarhus biocommunity. information about the Aarhus biocommunity. In addition, Aarhus scientists and managers train In addition, Aarhus scientists and managers train “Invest in Denmark” employees stationed “Invest in Denmark” employees stationed abroad, so to better represent Danish bioabroad, so to better represent Danish bio--interests internationally. interests internationally.


BMF marketing strategyBMF marketing strategy: : Innovation in promoting the cluster Innovation in promoting the cluster via specificvia specific--target audience journalstarget audience journals

Exposure of Danish competencies to MEPs, EC, Exposure of Danish competencies to MEPs, EC, using influential magazines like EU Parliament using influential magazines like EU Parliament ”Finance International” to access CEOs worldwide”Finance International” to access CEOs worldwideScandinavian Life Sciences journalScandinavian Life Sciences journalAccess to US bioAccess to US bio--community via journals like: community via journals like: Pharmaceutical Discovery (former Pharmaceutical Discovery (former PharmaGenomicsPharmaGenomics


The Parliament

Issue 173, 15th December 2003

p. 47


Spring 2005, p. 120 Spring 2005, p. 120 --121121


Scandinavian Life Science JournalScandinavian Life Science Journal

Issue 1 Issue 1 –– 2005, p. 31 2005, p. 31 -- 3232


Switzeland: Ambassador to help us in getting Switzeland: Ambassador to help us in getting connected with the senior management of the connected with the senior management of the Swiss Pharma: Novartis, RocheSwiss Pharma: Novartis, RocheUnited States: Ambassador and First Secretary United States: Ambassador and First Secretary arranged for meetings with US biotechs and arranged for meetings with US biotechs and influential USinfluential US--based academicsbased academicsCanada: Ambassador, IRAP network linked us Canada: Ambassador, IRAP network linked us with GenomeCanada with GenomeCanada

BMF strategyBMF strategy: : Innovation in MatchInnovation in Match--making activity making activity

via Embassy channelsvia Embassy channels


Innovation in Innovation in in R/D policyin R/D policy

The very rich The very rich LundbeckLundbeck fund is to dedicate fund is to dedicate Euro 35 M to help Danish researchers to Euro 35 M to help Danish researchers to stay in Denmark to researchstay in Denmark to research.. One of One of Denmark’s largest money tanks the Denmark’s largest money tanks the LundbeckLundbeck fund will now attract the best fund will now attract the best Danish brains abroad to return home to Danish brains abroad to return home to research to be of benefit to Denmark, research to be of benefit to Denmark, writes “writes “BerlingskeBerlingske Business”.Business”.

IdeaIdeaPolicyPolicyScienceScienceTechnologyTechnologyVC Banking VC Banking sectorsectorLobbyingLobbyingIntellectual Intellectual Property Property PublicPublic--Private Private Partnerships Partnerships Alliance Alliance ManagemenManagementt


BMF strategy: BMF strategy:

Innovation in biomapping activityInnovation in biomapping activityWestern Denmark electronic biomap projectWestern Denmark electronic biomap project

An innovative mapping project to:An innovative mapping project to:accurately map the Western Denmark accurately map the Western Denmark bioregion to bioregion to reveal reveal biocompetenciesbiocompetencies for the for the purpose of attracting foreign investments and purpose of attracting foreign investments and establishing research and business bioestablishing research and business bio--partnershippartnershipto to surfacesurface hidden know how potential, which hidden know how potential, which previously was not fully recognized previously was not fully recognized


Geographical ViewDatabase View

View All 5 divisions Select Area

Hospitals

Academia

Companies

All players

Network View

Bioinformatics

Health Biotech& Biomedical Supportive

F&A

Medicaltechnology

BMF

Product- based

Platform- based


Favorites:•Cbvbbfx ⊗•Vcxvfafa ⊗•Xvcvfagf ⊗•Bxvhg ⊗

ProductProductTechnologyTechnologyBiocompetenciesBiocompetencies Search:

Select: Select: XX All All □□ Companies Companies □□ Academia/HospitalsAcademia/Hospitals

Western Denmark BiocompetenciesWestern Denmark Biocompetencies

Keywords Pop-up when Mouse – over the UNIT of possible interest

Network View

List View

Bioin

Genetics

BiologyEnvironment

Biotechnology

com

Bioin

Genetics

BiologyEnvironment

Biotechnology

com

Bioin

Genetics

BiologyEnvironment

Biotechnology

com

Bvsbd bdbDbb

C ABCCB


BMF overall strategy:BMF overall strategy:Aarhus bioclusterAarhus biocluster to gain competitive to gain competitive

advantage in the global market advantage in the global market

To facilitate partnership between Danish and To facilitate partnership between Danish and foreign Biotechs/Pharma for codevelopment and foreign Biotechs/Pharma for codevelopment and outout--licensing of Danish technology/biolicensing of Danish technology/bio--products products To help Aarhus companies to gain competitive To help Aarhus companies to gain competitive advantage in the fierce world Bioadvantage in the fierce world Bio--arenaarenaTo considerably impact as biocluster in EuropeTo considerably impact as biocluster in Europe


Aarhus biocluster, DenmarkAarhus biocluster, DenmarkBiotech company categoriesBiotech company categories

Selected Drug Discovery Biotech companiesSelected Drug Discovery Biotech companiesSelected NonSelected Non--Drug Discovery Biotech Drug Discovery Biotech companiescompaniesSelected Selected Medical Technology companiesMedical Technology companiesFood and foodFood and food--supplement supplement companiescompanies


Action Action PharmaPharma:: Acute myocardial infarction and inflammatory diseasesAcute myocardial infarction and inflammatory diseases

ReceptIcon:ReceptIcon: Treatment of drugTreatment of drug--related adverse effects (organ damage) related adverse effects (organ damage) e.g.renale.g.renal cancercancer

CobentoCobento:: Production of recombinant therapeutic proteins in GMO plants foProduction of recombinant therapeutic proteins in GMO plants for r

treatment of vitamin B12 deficiency, which can lead to dementia treatment of vitamin B12 deficiency, which can lead to dementia and depressionand depression

BoreanBorean PharmaPharma:: TrimerizationTrimerization technology platform leading to development of humantechnology platform leading to development of human

protein drugs of high specificity. Application in a wide spectruprotein drugs of high specificity. Application in a wide spectrum of diseasesm of diseases

Cell Cure:Cell Cure: Development of patientDevelopment of patient--specific therapeutic protocols for metastatic Caspecific therapeutic protocols for metastatic Ca

Senentek:Senentek: development of advanced treatments for antidevelopment of advanced treatments for anti--aging (HQ in California)aging (HQ in California)

Aarhus biocluster, DenmarkAarhus biocluster, DenmarkSelected Drug Discovery Biotech Selected Drug Discovery Biotech companies companies ((moderate at national levelmoderate at national level))


Biotech company: Action Biotech company: Action PharmaPharmaEstablished:Established: 2000, 2000, Locations:Locations: HQ in Aarhus, office in Copenhagen,HQ in Aarhus, office in Copenhagen,

Focus:Focus: Discovery and development of new drugs and treatment concepts wDiscovery and development of new drugs and treatment concepts withinithin

diseases associated with ischemia and inflammation diseases associated with ischemia and inflammation

Key company informationKey company information::

R&D pipeline with preR&D pipeline with pre--clinical validated targets clinical validated targets

Company completing clinical development of selected program Company completing clinical development of selected program

OrphanOrphan drug indication and hence drug indication and hence “fast track” regulatory “fast track” regulatory advantagesadvantages

Strategic collaborations with two European biotech companiesStrategic collaborations with two European biotech companies

Several Several bnbn $ markets with attractive commercial perspectives$ markets with attractive commercial perspectives

BusinBusin. model: . model: outout--licensing opportunities supported by strong licensing opportunities supported by strong IPRIPR

Acquired total venture capital in excess of $ 3 M (2000Acquired total venture capital in excess of $ 3 M (2000--2005) from 2005) from local VCslocal VCs: : IncubaIncuba Ventures, Ventures, VækstfondenVækstfonden..


Action Action PharmaPharma (II)(II)((www.actionpharma.comwww.actionpharma.com))

Dermatitis (include atopic dermatitis and psoriasis), SIRS = systemic inflammatory response syndrom; AMI = acute myocardial infarction; ARF = acute renal failure; COPD = chronic obstructive pulmonary disease (with focus on acute inflammatory excerbations).


ArosAros Applied Biotechnology:Applied Biotechnology: Gene expression analysis by oligonucleotide chips and Gene expression analysis by oligonucleotide chips and

micromicro--array service provider. European pioneer in array service provider. European pioneer in AffymetrixAffymetrix chip analysischip analysis

DNA Technology:DNA Technology: CustomCustom--made oligonucleotides and molecular diagnostic kitsmade oligonucleotides and molecular diagnostic kits

ProteoTargetProteoTarget:: Phage display technology focused on malignant cell proliferatioPhage display technology focused on malignant cell proliferationn

LokeLoke Diagnostics:Diagnostics: Chlamydia and Chlamydia and MycoplasmaMycoplasma molecular diagnostic products and molecular diagnostic products and

vaccine development vaccine development

Pipeline Biotech: Pipeline Biotech: Pharmacological CRO offering prePharmacological CRO offering pre--clinical and pharmacokinetic clinical and pharmacokinetic

studiesstudies

Aarhus biocluster, DenmarkAarhus biocluster, DenmarkSelected NonSelected Non--Drug Discovery Biotech Drug Discovery Biotech

companiescompanies(moderate at national level(moderate at national level))


AROS Applied Biotechnology AROS Applied Biotechnology www.arosab.comwww.arosab.com

Established: 2000, by scientists at the Mol. Established: 2000, by scientists at the Mol. DiagnDiagn. Lab, AUH. Lab, AUH (University spin out)(University spin out)..

Key contactKey contact:: Torben Torben ØrntoftØrntoft. Employees. Employees:: 77

A leading A leading microarray service providermicroarray service provider and CRO for the and CRO for the

pharmaceutical industry and the academic community. pharmaceutical industry and the academic community. ArosAros was was

the first European institution to purchase an the first European institution to purchase an AffymetrixAffymetrix system system

(1999), and went into a (1999), and went into a business partnership with business partnership with AffymetrixAffymetrix

that has continued without interruptions ever since. Thus AROS ithat has continued without interruptions ever since. Thus AROS is s

official Service Provider for the complete product line of official Service Provider for the complete product line of

Affymetrix'sAffymetrix's genomic chip platforms.genomic chip platforms.


Aarhus biocluster, DenmarkAarhus biocluster, DenmarkSelected Selected Medical Technology companiesMedical Technology companies

((strong nationally & competitive in Europestrong nationally & competitive in Europe))Development and production of equipment forDevelopment and production of equipment for

VivoxVivox:: control of temperature & gas compositioncontrol of temperature & gas composition

CuratioCuratio:: Wound cleaningWound cleaning

Danish Danish MyoMyo Technology:Technology: MyographsMyographs for physiology and pharmacology studiesfor physiology and pharmacology studies

HistOtechHistOtech:: Preservation of the stereology/3D structure of pathological secPreservation of the stereology/3D structure of pathological sectionstions

Med. EngineeringMed. Engineering:: Pulse measuring and other handheld measurement devices Pulse measuring and other handheld measurement devices

NRT:NRT: XX--ray equipment development providing for GE and Philips among othray equipment development providing for GE and Philips among othersers

PysiotechPysiotech:: Physiotherapy and rehabilitationPhysiotherapy and rehabilitation

UnisenseUnisense:: MicrosensorsMicrosensors for environmental & IVF purposesfor environmental & IVF purposes


Aarhus biocluster, DenmarkAarhus biocluster, DenmarkFood and foodFood and food--supplement supplement companiescompanies

((very strong, internationally very strong, internationally competitive)competitive)

Modern biotechnology is an integrated part of the Aarhus food Modern biotechnology is an integrated part of the Aarhus food

large corporations: large corporations: ArlaArla, Aarhus United, Compact, Ceres, , Aarhus United, Compact, Ceres,

DaniscoDanisco andand Danish CrownDanish Crown -- and SMEs, which possess long track and SMEs, which possess long track

record & experience in:record & experience in:

Sugar and sugarSugar and sugar--derivatesderivates

Dairy products and derivates Dairy products and derivates

Oil and derivates Oil and derivates

Diverse equipment and machinery with focus on the food Diverse equipment and machinery with focus on the food

industryindustry


BMFBMFAarhus CountyAarhus County& Municipality& Municipality

UniversityUniversityAarhus Aarhus

UniversityUniversityHospitalHospital

StartStart--up up biotech and biotech and

med tech med tech companiescompanies

Biomedical Biomedical EngineerEngineer.

EU EU fundingfunding

Biotech Biotech companiescompanies

Big Big PharmaPharma

Invest: preInvest: pre--seed, seed,VCsseed, seed,VCs

BIOMARKETBIOMARKET

Biomedical

Biomedical

Science Park

Science Park

IPR IPR FirmsFirms

Invest in DenmarkInvest in Denmark

Aarhus biocluster, Aarhus biocluster, DenmarkDenmark

Aarhus Food industryAarhus Food industry


Innovation Zone Innovation Zone EnvironmentEnvironment

impact on impact on New New bioeconomybioeconomy


Innovation Innovation Zone/environmentZone/environment

An An Innovation Zone/EnvironmentInnovation Zone/EnvironmentNeeds to have access to first class research Needs to have access to first class research (first Max Plunk Institute outside Germany)(first Max Plunk Institute outside Germany)Supports the commercialisation of research Supports the commercialisation of research ideasideasIs critical to new technology innovative Is critical to new technology innovative SMEsSMEscan generate growth for the entire respective can generate growth for the entire respective regionregion


Innovative startInnovative start--ups give birth to ups give birth to New EconomyNew Economy

In any industry over 80% of all startIn any industry over 80% of all start--ups fail ups fail within five yearswithin five yearsWhat are the critical factors for a new What are the critical factors for a new technology companytechnology company--usually a spin out from usually a spin out from a universitya university--to sustain, become innovative to sustain, become innovative and achieve commercializationand achieve commercialization of its patentof its patent--protected research discoveries?protected research discoveries?


Critical factors for new technology Critical factors for new technology startstart--up companies to grow and up companies to grow and

sustain sustain Breakthrough research results to base your Breakthrough research results to base your business plansbusiness plansFollow scientific and technology trendsFollow scientific and technology trendsAccess to key business development personnel Access to key business development personnel (technology valuation, licensing, ..)(technology valuation, licensing, ..)Intellectual Property (patent Intellectual Property (patent portofolioportofolio))Negotiating Partnership/Alliance Negotiating Partnership/Alliance ManagementManagementInnovation Zone environment/clusterInnovation Zone environment/cluster


Dubai Innovation ZoneDubai Innovation Zoneworld class cluster and business world class cluster and business

hubhub

DuBiotech (Dubai biotechnology park)DuBiotech (Dubai biotechnology park)The Foundation for research and innovationThe Foundation for research and innovationDubai internet cityDubai internet cityDubai media cityDubai media cityKnowledge village and academic city Knowledge village and academic city


Completion of legislative framework in Completion of legislative framework in accordance with EU regulationsaccordance with EU regulationsCreation of Alexander Innovation Zone S.A. Creation of Alexander Innovation Zone S.A.

(AIZ)(AIZ)Operation of A.I.Z started mid summer 2007Operation of A.I.Z started mid summer 2007Initial funding received early Nov. 2007 after it Initial funding received early Nov. 2007 after it

was seriously cut from that originally requested. was seriously cut from that originally requested. As a result no personnel yet nor company offices As a result no personnel yet nor company offices rentrent

Thessaloniki Innovation ZoneThessaloniki Innovation Zone::Actions AccomplishedActions Accomplished


THESSALONIKITECHNOPOLIS

under construction(10 ha.- 70 tenants)

IT firms3 Business Incubators

(35 incubatees)

RESEARCH INSTITUTES &TECHNOLOGY PARK

Large state owned land (land reserve

for Innovation Zone)

THE SEA

Large private owned land (land reserve for Innovation Zone)

Thessaloniki Innovation Zone area Thessaloniki Innovation Zone area (current situation)(current situation)

TECHNOLOGY MUSEUM


Strategic Plan for the Thessaloniki Innovation Zone Strategic Plan for the Thessaloniki Innovation Zone (Under the auspices of Ministry of Macedonia(Under the auspices of Ministry of Macedonia--Thrace)Thrace)

Thessaloniki Innovation Zone land surveys, Spatial Thessaloniki Innovation Zone land surveys, Spatial planning, Master Plan planning, Master Plan (Under the auspices of Ministry of Macedonia(Under the auspices of Ministry of Macedonia--Thrace)Thrace)

Large state & private owned plots survey for candidate Large state & private owned plots survey for candidate areas to become part of the Innovation Zone areas to become part of the Innovation Zone [[SedesSedes old military old military airport (50 ha), AFS area adjacent to airport (50 ha), AFS area adjacent to TechnopolisTechnopolis, (30 ha), Min. of Agriculture (18 ha)], (30 ha), Min. of Agriculture (18 ha)]

Incentives for companies to settle within the Zone Incentives for companies to settle within the Zone (preliminary work completed) (preliminary work completed)

Thessaloniki Innovation ZoneThessaloniki Innovation ZoneAlexander Innovation Zone S.AAlexander Innovation Zone S.A.:.:

Actions in progressActions in progress


Plan for a Biotech cluster Plan for a Biotech cluster within within

the Thessaloniki Innovation the Thessaloniki Innovation Zone areaZone area


1. 1. InstituteInstitute ofof BiomedicalBiomedical andandBiomolecularBiomolecular ResearchResearch (IBBR(IBBR))

The The InstituteInstitute ofof BiomedicalBiomedical andand BiomolecularBiomolecularResearchResearch

(IBBR) (IBBR) waswas createdcreated in 2007. in 2007. IBBRIBBR goalsgoals are in are in thethesupportsupport

of of biomedicalbiomedical researchresearch basedbased onon a a multidisciplinarymultidisciplinaryapproachapproach amongstamongst variousvarious scientificscientific thematicthematic areasareas inin::

BBiomedicaliomedical informaticsinformatics, , BBiomedicaliomedical engineeringengineering, , MMolecularolecular medicinemedicine,, andandPharmacogeneticsPharmacogenetics//pharmacogenomicspharmacogenomics. .


1. 1. InstituteInstitute ofof BiomedicalBiomedical andandBiomolecularBiomolecular ResearchResearch (IBBR(IBBR))

TheThe InstituteInstitute aimsaims in in supportingsupporting research research developmentdevelopment

in in thethe basicbasic asas wellwell asas appliedapplied biobiomedicalmedical areaarea. . TheThedevelopmentdevelopment, , assessmentassessment andand standardizationstandardization ofofinnovativeinnovative researchresearch as well as as well as spinspin--offoff biotech and biotech and biomedical engineering biomedical engineering companiescompanies for the support for the support and uptake of innovative applicationsand uptake of innovative applications, services , services and and products products aimed at aimed at medical practice medical practice with with emphasiemphasis ons ondisease disease prevention and prevention and nonnon--invasive invasive treatment of treatment of

diseasesdiseases


2. 2. EconomouEconomou--KoskinasKoskinasBrain & Intelligence Brain & Intelligence Institute,Thes/nikiInstitute,Thes/niki

Basic NeurosciencesBasic Neurosciences

Structural and Functional NeuroscienceStructural and Functional NeuroscienceBehavioral and Cognitive NeuroscienceBehavioral and Cognitive Neuroscience

Applied NeurosciencesApplied Neurosciences

Decisions and Policy MakingDecisions and Policy MakingMind and CreativityMind and CreativitySpecial Education ApplicationsSpecial Education Applications

Sectors and Divisions


What we group under the name of the sciencesis, as the application of the word in the pluralshows, no single entity, but consists of manyseparate fields of knowledge, which often lie farapart. Through the increase of such knowledge, these fields increase, and their boundaries, originally far apart, approach each other moreand more. The investigation of these borderzones then becomes one of the most interestingproblems in science and a new branch ofscience itself, whereby the experience andmethods of one speciality are applied to theother and entirely new points of view arereached that lead to fruitful work in both fields.

– Constantin von Economo * (1931)

Atlas of Atlas of CytoarchitectonicsCytoarchitectonics of the Adult Human Cerebral Cortex of the Adult Human Cerebral Cortex EconomoEconomo C von, C von, KoskinasKoskinas GN, GN, TriarhouTriarhou LC (2008) LC (2008) KargerKarger, Basel, p. 171, Basel, p. 171


3. Investing in biomarker 3. Investing in biomarker technologytechnology

The use of biomarkers in BioPharma R&D and diagnosticswill enable more precise, predictive and preventive clinicalcare. Biomarker-enabled R&D is evolving into a newdiscipline with a strong patient focus. Many organizationsthat believe in biomarker enabled R&D, are investing in biomarker technology. Many leading companies, such asNovartis, Eli Lilly, Bristol-Myers Squibb, Pfizer and Bayer, have developed new R&D processes based on theuse of biomarkers throughout the clinical trials process forcardiology, oncology and neurology.

IBM Global Business Services


3a. Biomarkers & Imaging field3a. Biomarkers & Imaging field

In the imaging field, biomarkers are increasingly beingused non-invasively to assess

patients’ localized disease progression andresponse to drug candidates

Biomarkers can help determine whetherthe drug reaches the target, it affects biological activity, and, if it does, whether that effect leads to thedesired clinical outcome



3b. Biomarkers in clinical trials 3b. Biomarkers in clinical trials

Innovative strategies are needed for biomarkerdiscovery and validation that parallel theapproach to therapeutics. A collaborativeapproach to biomarker discovery usingstandardized tissue and biological fluidspecimens, ideally collected as part of clinicaltrials, has the potential to Fasttrack biomarkerdiscovery


3c. Biomarkers pave the way for Information-Based Medicine

Biomarkers are becoming a foundation for information-based medicine in determining who should be treated, how and with what. For biomarkers to reach their fullpotential, alone or in combination, they must undergotheir own development process. Biomarker developmenthas lagged significantly behind therapeutic developmentbecause of scientific, economic and regulatory factors. Itis important to accelerate biomarker development and tohelp biomarkers advance in parallel with therapeutics,but, they must be tested with established therapies



3d. Biomarkers Value for3d. Biomarkers Value forthe biotech companiesthe biotech companies

Biomarkers provide increasing value as companiesmove along the path from drug discovery to productlaunch because:

Costs go up at each progressive stage.More knowledge is needed to reduce risks atprogressive stages.Regulatory “proof” requires more rigor as oneapproaches approval “stage-gates.”Technique and technology must be “locked down” through the multiyear clinical phases



3e. Biomarker Consortium: Innovation in PPP NIH approach to speed up

clinical useThe Biomarker Consortium is a program sponsored by the Foundationfor the National Institutes of Health to bring private and publicpartners together to support the NIH vision. Its strategy is to create“harmonized approaches” to speed up biomarker value and formal useto promote research, regulatory approval, and more informed decisions. The Consortium carefully develops policies to address IP concerns, data sharing, antitrust issues, grantee/contractor selection, confidentiality and conflicts of interest. Currently, the BiomarkerConsortium is focusing on three projects:• Neuroscience: Major Depressive Disorder – identifying its genomic

biomarkers• Metabolic diseases: Such as diabetes• Oncology: FDG-PET for lung cancer and lymphoma



4. Outsourcing 4. Outsourcing biomanufacturingbiomanufacturing in in the Thessaloniki Innovation Zonethe Thessaloniki Innovation Zone

Biotech companies will rely upon an outsourced business Biotech companies will rely upon an outsourced business model like the 60% of pharma industry. This is true for model like the 60% of pharma industry. This is true for bioregions as well. A region doesn’t have to build itself up bioregions as well. A region doesn’t have to build itself up

as as another San Diego. For instance a company in Seattle can another San Diego. For instance a company in Seattle can have manufacturing in Carolina, marketing offices in have manufacturing in Carolina, marketing offices in

New New Jersey, and clinical trial in Kansas. Regions with specific Jersey, and clinical trial in Kansas. Regions with specific strengths in this outsourced business model will be strengths in this outsourced business model will be interconnected with each otherinterconnected with each other


RocheRoche HoldingHolding AGAG toto InvestInvest aboutabout$400M $400M toto ExpandExpand BiotechBiotech OperationsOperations

1/18/20081/18/2008

ZURICH (ZURICH (MarketWatchMarketWatch) ) ---- RocheRoche HoldingHoldingAG AG FridayFriday saidsaid itit plansplans toto investinvest $391 $391 millionmilliontoto expandexpand biotechbiotech drugdrug researchresearch, , developmentdevelopment andand productionproduction atat sitessites ininSwitzerlandSwitzerland andand GermanyGermany..

innovation management: experience from the danish biotech ...€¦ · alexander innovation zone...

Documents